Ignite Creation Date:
2024-05-06 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05689528
Status:
COMPLETED
Last Update Posted:
2023-01-19
First Post:
2021-12-19
Brief Title:
The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neuroprotection is expected to be an important therapeutic strategy for acute ischemic strokeAIS but almost all neuroprotective drugs proved effective in rodent models have failed after entering clinical trials This study aims to screen the differentially expressed proteins in peripheral blood of patients with acute ischemic stroke and with further study in the animal model of non-human primate cerebral infarction we may determine the biomarkers that can evaluate the efficacy of neuroprotective drugs
Detailed Description:
Acute ischemic stroke AIS is a major disease which cause death and disability Globally ischemic stroke is the second most common cause of death from vascular diseases and the third most common cause of disability For decades neuroprotection has been highly expected as an important treatment for cerebral ischemia but almost all neuroprotective drugs proved effective in rodent models have failed in clinical trials In this study we enrolled patients with acute ischemic stroke collecting their peripheral blood samples at 1 day and 3 months of onset Neuropsychological scales evaluation and imaging evaluation were also completed at 1 day 7 day and 3 months of onset respectively Correlation research in combination with the patients clinical information were conducted to preliminarily screen the proteins related to the prognosis of neurological function which was reflected by patients mRS scores at 3 months of onset in peripheral blood Further study in the animal model of non-human primate cerebral infarction may determine the biomarkers that can evaluate the efficacy of neuroprotective drugs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None